Cargando…

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

We retrospectively studied 125 patients with acute myeloid leukemia and trisomy 4 (median age at diagnosis, 58 years; range, 16-77 years) treated between 2000 and 2019 within a multicenter study. Trisomy 4 was the sole abnormality in 28 (22%) patients and additional abnormalities were present in 97...

Descripción completa

Detalles Bibliográficos
Autores principales: Kayser, Sabine, Martínez-Cuadrón, David, Hanoun, Maher, Stölzel, Friedrich, Gil, Cristina, Reinhardt, H. Christian, Aguiar, Eliana, Schäfer-Eckart, Kerstin, Burgues, Juan Miguel Bergua, Steffen, Björn, Bernal, Teresa, Krause, Stefan W., Riaza, Rosalía, Schliemann, Christoph, Cervera, Jose, Kaufmann, Martin, Torres-Miñana, Laura, Hänel, Mathias, Acuña-Cruz, Evelyn, Jost, Edgar, Algarra, Jesus Lorenzo, Crysandt, Martina, Fransecky, Lars, Cornago-Navascues, Javier, Kraus, Sabrina, Martinez-Lopez, Joaquin, Einsele, Hermann, Niemann, Dirk, Neubauer, Andreas, Seggewiss-Bernhardt, Ruth, Scholl, Sebastian, Klein, Stefan A., Schmid, Christoph, Schaich, Markus, Schmidt-Hieber, Martin, Zukunft, Sven, Ho, Anthony D., Platzbecker, Uwe, Baldus, Claudia D., Müller-Tidow, Carsten, Thiede, Christian, Bornhäuser, Martin, Serve, Hubert, Levis, Mark J., Montesinos, Pau, Röllig, Christoph, Schlenk, Richard F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827151/
https://www.ncbi.nlm.nih.gov/pubmed/35678031
http://dx.doi.org/10.3324/haematol.2022.281137
Descripción
Sumario:We retrospectively studied 125 patients with acute myeloid leukemia and trisomy 4 (median age at diagnosis, 58 years; range, 16-77 years) treated between 2000 and 2019 within a multicenter study. Trisomy 4 was the sole abnormality in 28 (22%) patients and additional abnormalities were present in 97 (78%) patients. Twenty-two (22%) and 15 (15%) of 101 tested patients harbored NPM1 and FLT3-ITD mutations. Two (3%) of 72 tested patients had double CEBPA mutations. Data on response to intensive anthracycline-based induction therapy were available for 119 patients. Complete remission was achieved in 67% (n=80) and the early death rate was 5% (n=6). Notably, patients with trisomy 4 as sole abnormality had a complete remission rate of 89%. Allogeneic hematopoietic cell transplantation was performed in 40 (34%) patients, of whom 19 were transplanted in first complete remission. The median follow-up of the intensively treated cohort was 5.76 years (95% confidence interval [95% CI]: 2.99-7.61 years). The 5-year overall survival and relapse-free survival rates were 30% (95% CI: 22-41%) and 27% (95% CI: 18-41%), respectively. An Andersen-Gill regression model on overall survival revealed that favorable-risk according to the European LeukemiaNet classification (hazard ratio [HR]=0.34; P=0.006) and trisomy 4 as sole abnormality (HR=0.41; P=0.01) were favorable factors, whereas age with a difference of 10 years (HR=1.15; P=0.11), female gender (HR=0.74; P=0.20) and allogeneic hematopoietic cell transplantation (HR=0.64; P=0.14) did not have an significant impact. In our cohort, patients with trisomy 4 as their sole abnormality had a high complete remission rate and favorable clinical outcome. Allogeneic hematopoietic cell transplantation did not seem to improve overall survival.